## Electronic Supplementary Information for

## New synthesis of phenyl-isothiocyanates *C*-functionalised cyclams. Bioconjugation and <sup>64</sup>Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative

Zakaria Halime,<sup>a</sup> Mathieu Frindel,<sup>a,b</sup> Nathalie Camus,<sup>a</sup> Pierre-Yves Orain,<sup>a</sup> Marie Lacombe,<sup>c</sup> Michel Chérel,<sup>c</sup> Jean-François Gestin<sup>c</sup>, Alain Faivre-Chauvet<sup>c</sup> and Raphaël Tripier<sup>a,\*</sup>

<sup>&</sup>lt;sup>a.</sup> Université de Brest, UMR-CNRS 6521 / SFR148 ScInBioS, UFR Sciences et Techniques, 6 Avenue Victor le Gorgeu, C.S. 93837, 29238 BREST, France.

<sup>&</sup>lt;sup>b.</sup> Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Unité INSERM 892 - CNRS 6299, 8 quai Moncousu, BP 70721 44007 Nantes Cedex, France.

<sup>&</sup>lt;sup>c.</sup> Institut de Cancérologie de l'Ouest, 44800 Saint-Herblain, France.

## Table of contents

Figure S1. <sup>1</sup> H NMR spectrum	5
Figure S2. <sup>13</sup> C NMR spectrum	5
Figure S3. HRMS spectrum	6
Compound 5	7
Figure S4. <sup>1</sup> H NMR spectrum	8
Figure S5. <sup>13</sup> C NMR spectrum	8
Figure S6. HRMS spectrum	9
Compound 6	1(
Figure S7. <sup>1</sup> H NMR spectrum	11
Figure S8. <sup>13</sup> C NMR spectrum	11
Figure S9. HRMS spectrum	12
Compound 7	
Figure S10. 'H NMR spectrum	14
Figure S11. <sup>13</sup> C NMR spectrum	14
Figure S12. HRMS spectrum	15
Compound 8	
Figure S13. <sup>1</sup> H NMR spectrum	17
Figure S14. <sup>13</sup> C NMR spectrum	17
Figure S15. HRMS spectrum	18
Compound 9	
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum	<b>1</b> 9
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum	20 20 20
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum Figure S18. HRMS spectrum	<b>1</b> 9 20 20 21
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum Figure S18. HRMS spectrum Compound 10	20 20 21 <b>2</b> 2
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum Figure S18. HRMS spectrum Compound 10 Figure S19. <sup>1</sup> H NMR spectrum	20 20 21 
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum Figure S18. HRMS spectrum Compound 10 Figure S19. <sup>1</sup> H NMR spectrum Figure S20. <sup>13</sup> C NMR spectrum	20 20 21 <b>2</b> 23 23
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum Figure S18. HRMS spectrum Compound 10 Figure S19. <sup>1</sup> H NMR spectrum Figure S20. <sup>13</sup> C NMR spectrum Figure S21. HRMS spectrum	20 20 21 21 23 23 23 24
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum Figure S18. HRMS spectrum Compound 10 Figure S19. <sup>1</sup> H NMR spectrum Figure S20. <sup>13</sup> C NMR spectrum Figure S21. HRMS spectrum Compound 11	20 20 21 23 23 24 24
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum Figure S18. HRMS spectrum Compound 10 Figure S19. <sup>1</sup> H NMR spectrum Figure S20. <sup>13</sup> C NMR spectrum Figure S21. HRMS spectrum Figure S22. <sup>1</sup> H NMR spectrum	20 20 21 23 23 23 24 26
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum Figure S18. HRMS spectrum Compound 10 Figure S19. <sup>1</sup> H NMR spectrum Figure S20. <sup>13</sup> C NMR spectrum Figure S21. HRMS spectrum Compound 11 Figure S22. <sup>1</sup> H NMR spectrum Figure S23. <sup>13</sup> C NMR spectrum	20 20 21 23 23 23 24 24 26 26 26
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum Figure S18. HRMS spectrum Compound 10 Figure S20. <sup>1</sup> H NMR spectrum Figure S20. <sup>13</sup> C NMR spectrum Figure S21. HRMS spectrum Figure S22. <sup>1</sup> H NMR spectrum Figure S23. <sup>13</sup> C NMR spectrum Figure S24. HRMS spectrum	20 20 21 23 23 23 24 26 26 26 27
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum Figure S18. HRMS spectrum Compound 10 Figure S20. <sup>1</sup> H NMR spectrum Figure S20. <sup>13</sup> C NMR spectrum Figure S21. HRMS spectrum Figure S22. <sup>1</sup> H NMR spectrum Figure S23. <sup>13</sup> C NMR spectrum Figure S23. <sup>13</sup> C NMR spectrum Figure S24. HRMS spectrum Figure S24. HRMS spectrum	20 20 21 23 23 23 24 26 26 26 27 28
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum Figure S18. HRMS spectrum Figure S19. <sup>1</sup> H NMR spectrum Figure S20. <sup>13</sup> C NMR spectrum Figure S21. HRMS spectrum Figure S22. <sup>1</sup> H NMR spectrum Figure S23. <sup>13</sup> C NMR spectrum Figure S24. HRMS spectrum Figure S24. HRMS spectrum Figure S25. <sup>1</sup> H NMR spectrum	20 20 21 23 23 23 24 26 26 26 26 27 28 29
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum Figure S18. HRMS spectrum Compound 10 Figure S20. <sup>13</sup> C NMR spectrum Figure S21. HRMS spectrum Figure S22. <sup>1</sup> H NMR spectrum Figure S23. <sup>13</sup> C NMR spectrum Figure S24. HRMS spectrum Figure S24. HRMS spectrum Figure S25. <sup>1</sup> H NMR spectrum Figure S26. <sup>13</sup> C NMR spectrum Figure S26. <sup>13</sup> C NMR spectrum	
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum Figure S18. HRMS spectrum Compound 10 Figure S20. <sup>13</sup> C NMR spectrum Figure S21. HRMS spectrum Figure S22. <sup>1</sup> H NMR spectrum Figure S23. <sup>13</sup> C NMR spectrum Figure S24. HRMS spectrum Figure S24. HRMS spectrum Figure S25. <sup>1</sup> H NMR spectrum Figure S26. <sup>13</sup> C NMR spectrum Figure S27. HRMS spectrum	20 20 21 23 23 23 24 26 26 26 26 27 29 29 30
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum Figure S18. HRMS spectrum Compound 10 Figure S20. <sup>13</sup> C NMR spectrum Figure S21. HRMS spectrum Figure S21. HRMS spectrum Figure S22. <sup>1</sup> H NMR spectrum Figure S23. <sup>13</sup> C NMR spectrum Figure S24. HRMS spectrum Figure S25. <sup>1</sup> H NMR spectrum Figure S25. <sup>1</sup> H NMR spectrum Figure S26. <sup>13</sup> C NMR spectrum Figure S27. HRMS spectrum Figure S27. HRMS spectrum	20 20 21 21 23 23 23 24 26 26 26 26 27 28 29 29 30 37
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum Figure S18. HRMS spectrum Compound 10 Figure S20. <sup>13</sup> C NMR spectrum Figure S21. HRMS spectrum Figure S21. HRMS spectrum Figure S23. <sup>13</sup> C NMR spectrum Figure S24. HRMS spectrum Figure S24. HRMS spectrum Figure S25. <sup>1</sup> H NMR spectrum Figure S26. <sup>13</sup> C NMR spectrum Figure S27. HRMS spectrum Figure S27. HRMS spectrum Figure S28. <sup>1</sup> H NMR spectrum	20 20 21 23 23 23 24 24 24 24 24 24 24 24 24 24
Compound 9 Figure S16. <sup>1</sup> H NMR spectrum Figure S17. <sup>13</sup> C NMR spectrum Figure S18. HRMS spectrum Compound 10 Figure S20. <sup>13</sup> C NMR spectrum Figure S21. HRMS spectrum Figure S22. <sup>1</sup> H NMR spectrum Figure S23. <sup>13</sup> C NMR spectrum Figure S24. HRMS spectrum Figure S24. HRMS spectrum Figure S25. <sup>1</sup> H NMR spectrum Figure S25. <sup>1</sup> H NMR spectrum Figure S26. <sup>13</sup> C NMR spectrum Figure S26. <sup>13</sup> C NMR spectrum Figure S27. HRMS spectrum Figure S27. HRMS spectrum Figure S28. <sup>1</sup> H NMR spectrum Figure S28. <sup>1</sup> H NMR spectrum Figure S28. <sup>1</sup> H NMR spectrum Figure S29. <sup>13</sup> C NMR spectrum Figure S29. <sup>13</sup> C NMR spectrum	20 20 20 21 23 23 23 24 26 26 26 26 27 28 29 29 30 32 32 32 32 32 32 32

Compound 14		. 34
Figure S31. IR spectrum	35	
Figure S32. HRMS spectrum	36	
Compound 15		. 37
Figure S33. <sup>1</sup> H NMR spectrum	38	
Figure S34. <sup>13</sup> C NMR spectrum	38	
Figure S35. HRMS spectrum	39	
Compound 16		. 40
Figure S36. IR spectrum	41	
Figure S37. HRMS spectrum	42	
Compound 17		. 43
Figure S38. <sup>1</sup> H NMR spectrum	44	
Figure S39. <sup>13</sup> C NMR spectrum	44	
Figure S40. HRMS spectrum	45	
Compound 18		. 46
Figure S41. IR spectrum	47	
Figure S42. HRMS spectrum	48	
Table 1S1. Conditions used to optimize the <sup>64</sup> Cu radiolabeling of 9E7.4-CSN-	Ph-te2a	49
Table TS2. Radiolabeling monitoring of <sup>64</sup> Cu-mAb-CSN-Ph-te2a by at differer	nt pH,	
temperature, time		49
Table TS3. In vitro competition assay of <sup>64</sup> Cu-mAb-CSN-Ph-te2a and <sup>64</sup> Cu-te2	2a-Ph-NCS	
against EDTA (10000 eq.)		49

Table TS4. Raw quantitative information data extracted from PET-CT image ofsubcutaneous multiple myeloma tumor bearing mice at 2 h and 20 h post-injection (PI) of64Cu-9E7.4-CSN-Ph-te2a	49
Figure S43. Biodistribution of <sup>125</sup> I-9E7.4	.50

## Compound 4:



Chemical Formula: C<sub>19</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub> Exact Mass: 357,2165 Molecular Weight: 357,4500 m/z: 357.2165 (100.0%), 358.2198 (20.5%), 359.2232 (2.0%), 358.2135 (1.8%)



Figure S1. <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>, 25 °C) of compound 4



5



Figure S3. HRMS spectrum (ESI) of compound 4

Compound 5:



 $\begin{array}{c} \mbox{Chemical Formula: } C_{33}H_{41}Br_2N_5O_2 \\ \mbox{Exact Mass: 697,1627} \\ \mbox{Molecular Weight: 699,5189} \\ \mbox{m/z: 699.1607 (100.0\%), 697.1627 (51.4\%), 701.1586 (48.6\%), 700.1640} \\ \mbox{(35.7\%), 698.1661 (18.3\%), 702.1620 (17.4\%), 701.1674 (6.2\%), 699.1694} \\ \mbox{(3.2\%), 703.1653 (3.0\%), 700.1577 (1.8\%)} \end{array}$ 



Figure S4. <sup>1</sup>H NMR spectrum (300 MHz, <sup>6</sup>d-DMSO, 25 °C) of compound 5



Figure S5. <sup>13</sup>C NMR spectrum (300 MHz, <sup>6</sup>d-DMSO, 25 °C) of compound 5



Figure S6. HRMS spectrum (ESI) of compound 5

Compound 6:



Chemical Formula: C<sub>31</sub>H<sub>41</sub>N<sub>5</sub>O<sub>2</sub> Exact Mass: 515,3260 Molecular Weight: 515,6895 m/z: 515.3260 (100.0%), 516.3294 (33.5%), 517.3327 (5.4%), 516.3231 (1.8%)



Figure S7. <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>, 25 °C) of compound 6



Figure S8. <sup>13</sup>C NMR spectrum (300 MHz, CDCl<sub>3</sub>, 25 °C) of compound 6



Figure S9. HRMS spectrum (ESI) of compound 6

Compound 7:



Chemical Formula: C<sub>43</sub>H<sub>61</sub>N<sub>5</sub>O<sub>6</sub> Exact Mass: 743,4622 Molecular Weight: 743,9743 m/z: 743.4622 (100.0%), 744.4655 (46.5%), 745.4689 (10.6%), 744.4592 (1.8%), 746.4722 (1.6%), 745.4664 (1.2%)



Figure S10. <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>, 25 °C) of compound 7



Figure S11.  $^{13}\text{C}$  NMR spectrum (300 MHz, CDCl\_3, 25 °C) of compound 7



Figure S12. HRMS spectrum (ESI) of compound 7

Compound 8:



Chemical Formula: C<sub>29</sub>H<sub>51</sub>N<sub>5</sub>O<sub>4</sub> Exact Mass: 533,3941 Molecular Weight: 533,7463 m/z: 533.3941 (100.0%), 534.3975 (31.4%), 535.4008 (4.7%), 534.3911 (1.8%)



Figure S13. <sup>1</sup>H NMR spectrum (300 MHz, CDCI<sub>3</sub>, 25 °C) of compound 8



Figure S14. <sup>13</sup>C NMR spectrum (300 MHz, CDCl<sub>3</sub>, 25 °C) of compound 8



Figure S15. HRMS spectrum (ESI) of compound 8

Compound 9:



Chemical Formula: C<sub>41</sub>H<sub>71</sub>N<sub>5</sub>O<sub>8</sub> Exact Mass: 761,5303 Molecular Weight: 762,0311 m/z: 761.5303 (100.0%), 762.5336 (44.3%), 763.5370 (9.6%), 762.5273 (1.8%), 763.5345 (1.6%), 764.5403 (1.3%)



Figure S16. <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>, 25 °C) of compound 9



Figure S17. <sup>13</sup>C NMR spectrum (300 MHz, CDCl<sub>3</sub>, 25 °C) of compound 9



Figure S18. HRMS spectrum (ESI) of compound 9

Compound 10:



Chemical Formula: C<sub>33</sub>H<sub>43</sub>N<sub>5</sub>O<sub>2</sub> Exact Mass: 541,3417 Molecular Weight: 541,7268 m/z: 541.3417 (100.0%), 542.3450 (35.7%), 543.3484 (6.2%), 542.3387 (1.8%)



Figure S19. <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>, 25 °C) of compound 10



Figure S20. <sup>13</sup>C NMR spectrum (300 MHz, CDCl<sub>3</sub>, 25 °C) of compound 10



Figure S21. HRMS spectrum (ESI) of compound 10

Compound 11:



Chemical Formula: C<sub>19</sub>H<sub>33</sub>N<sub>5</sub> Exact Mass: 331,2736 Molecular Weight: 331,4988 m/z: 331.2736 (100.0%), 332.2770 (20.5%), 333.2803 (2.0%), 332.2706 (1.8%)





Figure S23. <sup>13</sup>C NMR spectrum (300 MHz, CDCl<sub>3</sub>, 25 °C) of compound 11



Figure S24. HRMS spectrum (ESI) of compound 11

Compound 12:



Chemical Formula: C<sub>31</sub>H<sub>53</sub>N<sub>5</sub>O<sub>4</sub> Exact Mass: 559,4098 Molecular Weight: 559,7836 m/z: 559.4098 (100.0%), 560.4131 (33.5%), 561.4165 (5.4%), 560.4068 (1.8%)



Figure S25. <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>, 25 °C) of compound **12** 



Figure S26. <sup>13</sup>C NMR spectrum (300 MHz, CDCl<sub>3</sub>, 25 °C) of compound 12





Figure S27. HRMS spectrum (ESI) of compound 12

+33 (0)2 38 49 46 61

Compound 13:



Chemical Formula: C<sub>21</sub>H<sub>35</sub>N<sub>5</sub>O<sub>4</sub> Exact Mass: 421,2689 Molecular Weight: 421,5337 m/z: 421.2689 (100.0%), 422.2723 (22.7%), 423.2756 (2.5%), 422.2659 (1.8%)



Figure S28. <sup>1</sup>H NMR spectrum (300 MHz, D<sub>2</sub>O, 25 °C) of compound 13



Figure S29.  $^{13}\text{C}$  NMR spectrum (300 MHz, D2O, 25 °C) of compound 13



Institut de Chimie Organique et Analytique printed: 27/09/2013 19:42:31 UMR 7311 - Universite d'Orleans - CNRS Page 1 of 1 BP 6759 - rue de Chartres - F-45067 ORLEANS Cedex 2

cyril.colas@univ-orleans.fr +33 (0)2 38 49 46 61

Figure S30. HRMS spectrum (ESI) of compound 13

Compound 14:



Chemical Formula: C<sub>22</sub>H<sub>33</sub>N<sub>5</sub>O<sub>4</sub>S Exact Mass: 463,2253 Molecular Weight: 463,5935 m/z: 463.2253 (100.0%), 464.2287 (23.8%), 465.2211 (4.5%), 465.2320 (2.7%), 464.2224 (1.8%), 466.2245 (1.1%)



Figure S31. IR spectrum of compound 14



Institut de Chimie Organique et Analytique	printed:	09/10/2013 21:59:22
UMR 7311 - Universite d'Orleans - CNRS		Page 1 of 1
BP 6759 - rue de Chartres - F-45067 ORLEANS Cedex 2		
cyril.colas@univ-orleans.fr +33 (0)2 38 49 46 61		

Figure S32. HRMS spectrum (ESI) of compound 14

Compound 15:





Figure S33. <sup>1</sup>H NMR spectrum (300 MHz, D<sub>2</sub>O, 25 °C) of compound 15



Figure S34. <sup>13</sup>C NMR spectrum (300 MHz, D<sub>2</sub>O, 25 °C) of compound 15



Figure S35. HRMS spectrum (ESI) of compound 15

Compound 16:



 $\begin{array}{c} \mbox{Chemical Formula: $C_{26}H_{37}N_5O_8S$} \\ \mbox{Exact Mass: 579,2363} \\ \mbox{Molecular Weight: 579,6657} \\ \mbox{m/z: 579.2363 (100.0\%), 580.2396 (28.1\%), 581.2321 (4.5\%), 581.2430 (3.8\%), 580.2333 (1.8\%), 581.2405 (1.6\%), 582.2354 (1.3\%) \\ \end{array}$ 



Figure S36. IR spectrum of compound 16



Figure S37. HRMS spectrum (ESI) of compound 16

Compound 17:



Chemical Formula: C<sub>23</sub>H<sub>37</sub>N<sub>5</sub>O<sub>4</sub> Exact Mass: 447,2846 Molecular Weight: 447,5710 m/z: 447.2846 (100.0%), 448.2879 (24.9%), 449.2913 (3.0%), 448.2816 (1.8%)



Figure S38. <sup>1</sup>H NMR spectrum (300 MHz, D<sub>2</sub>O, 25 °C) of compound 17



Figure S39. <sup>13</sup>C NMR spectrum (300 MHz, D<sub>2</sub>O, 25 °C) of compound 17



Figure S40. HRMS spectrum (ESI) of compound 17

Compound 18:



Chemical Formula: C<sub>24</sub>H<sub>35</sub>N<sub>5</sub>O<sub>4</sub>S Exact Mass: 489,2410 Molecular Weight: 489,6308 m/z: 489.2410 (100.0%), 490.2443 (26.0%), 491.2368 (4.5%), 491.2477 (3.2%), 490.2380 (1.8%), 492.2401 (1.2%)



Figure S41. IR spectrum of compound 18



Figure S42. HRMS spectrum (ESI) of compound 18

Test n°	Molar ratio : Immunoconjugate/Cu or Ligand/Cu	Acetate buffer (pH)	Time (min)	Temp.
1	1.1	7	5, 15, 30, 60	RT
2	1.1	7	5, 15, 30, 60	40°C
3	1.1	5	5, 15, 30, 60	40°C
4	1.1	7	30	4°C

**Table TS1.** Conditions used to optimize the <sup>64</sup>Cu radiolabeling of 9E7.4-CSN-Ph-te2a and <sup>64</sup>Cu-te2a-Ph-NCS

**Table TS2.** In vitro competition assay of <sup>64</sup>Cu-9E7.4-CSN-Ph-te2a and <sup>64</sup>Cu-te2a-Ph-NCS against EDTA (10000 eq.) (conditions are presented in experimental part).

	<sup>64</sup> Cu-9E7.4-CSN-Ph-te2a	<sup>64</sup> Cu-te2a-Ph-NCS
Before incubation of EDTA	93 %	98 %
After one night incubation at RT		
with EDTA	51 %	56 %

Results are expressed as radiolabeling yield

**Table TS3.** Raw quantitative data extracted from PET-CT image of subcutaneous multiple myeloma tumor bearing mice at 2 h and 20 h post-injection (PI) of <sup>64</sup>Cu-9E7.4-CSN-Ph-te2a.

2 h Post Injection								
VOI	Tumor	Liver	Heart	Muscle (back leg)	bladder	gut	kidney	
Max (kBq/ml)	364.6	1625.9	1198.2	84.5	220.8	1351.6	542	
Average	178.4	1136.5	300.4	41.1	116.4	522.7	217.4	
Standard	95.9	244.5	223.9	14.8	40.9	212.9	121.9	
Volume (mm3)	343	343	343	38.9	53.7	340	13	
			20 h P	ost Injection				
VOI Tumor Liver Heart Muscle (back leg) bladder gut kidn								
Max (kBq/ml)	279.9	505.5	221.4	41.8	146.2	361.4	164,1	
Average	112.7	315.9	110.2	17.0	68	164.5	96	
Standard	60.2	85.8	39.4	6.4	27.6	68.7	37.9	
Volume (mm3)	339	339	339	40.3	53.9	339	13	

The volumes of interest (VOI) were manually plotted to assess the uptake of organs and tumor (in *kBq/ml*) by using AW Volume Share 5 (AW 4.6) software from General Electric.

**Table TS4.** Radiolabeling monitoring of <sup>64</sup>Cu-9E7.4-CSN-Ph-te2a (a) and <sup>64</sup>Cu-te2a-Ph-NCS (b) at different pH and temperature conditions.

	pH 7; RT		pH 7; 40°C		pH 5; 40°C		рН 7; 4°С	
	а	b	а	b	а	b	а	b
5 min	62 %	30 %	63 %	72 %	73 %	64 %	-	-
15 min	78 %	74 %	86 %	84 %	86 %	70 %	-	-
30 min	80 %	-	89 %	-	86 %	-	71 %	-
60 min	82 %	88 %	90 %	90 %	91 %	93 %	-	-



**Figure S43.** Biodistribution of <sup>125</sup>I-9E7.4 in subcutaneous multiple myeloma tumor bearing mice showing the large uptake in liver and gut especially at 21h post-injection.

**Figure S44. Characterization of 9E7.4 mAb specificity by flow cytometry**. Staining with 9E7.4 mAb (black histogram) and an IgG2a,κ isotype control (white histogram) followed by a PE-conjugated anti-rat IgG secondary antibody was performed on CD138+ 5T33 cell line. Flow cytometry was performed on a BD FACS Calibur™ Flow Cytometry System.

